When do you combine hypomethylating agents with venetoclax or gemtuzumab ozogamicin in elderly patients with AML who are ineligible for intensive chemotherapy?
1 Answers
Mednet Member
Medical Oncology · Columbia University Medical Center
In September, 2017, the FDA granted approval for gemtuzumab ozogamicin (GO) in combination with daunorubicin and cytarabine (DA) and as a monotherapy for the treatment of adult patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML). Approval of GO monotherapy was based on a randomi...